Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
  • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
  • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
  • C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
  • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
  • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
  • C07C45/305—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation with halogenochromate reagents, e.g. pyridinium chlorochromate
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
  • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/56—Ring systems containing three or more rings
  • C07D209/80—[b, c]- or [b, d]-condensed
  • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Definitions

• the present invention relates to pyrrolo [3,4-d] [2] -benzazepine derivatives of the general formula wherein R 1 and R 3 are hydrogen, (C 1 -C 7 ) alkyl, hydroxy, (C, -C 7 ) alkoxy or the group ⁇ OCOR ', R' is hydrogen, (C 1 -C 6 ) alkyl or Phenyl and R 2 and R 4 are hydrogen or R 1 and R 2 and / or R 3 and R 4 together are oxo groups, with the proviso that at least one oxo group is present, R is hydrogen, (C 1 -C 7 ) -Alkyl, hydroxy- (C 2 -C 7 ) -alkyl, amino- (C 2 -C 7 ) -alkyl or mono- or di- (C 1 -C 7 ) -alkylamino- (C 2 -C 7 ) -alkyl or the group - (C 1 -C 6
• EP-A2-45 519 describes pyrrolo [3,4-d] [2] benzazepines which have no oxo group (s) on the pyrrole ring.
• halogen with an atomic number not exceeding 35 denotes bromine, chlorine or fluorine, unless stated otherwise.
• alkyl denotes straight-chain or branched hydrocarbon residues, preferably C 1 -C 4 hydrocarbon residues, such as methyl, ethyl, propyl or isopropyl.
• salts encompasses both salts with inorganic and salts with organic, pharmaceutically acceptable acids, such as sulfuric acid, hydrochloric acid, nitric acid, methanesulfonic acid and p-toluenesulfonic acid.
• Such salts can be readily prepared by those skilled in the art in view of the state of the art and the nature of the compound to be salted.
• Preferred compounds in the context of the present inventions are those of the formula I, ie the Schiff bases. Furthermore, those compounds of the formula I are preferred in which R 3 and R 4 together represent an oxo group. Those compounds of the formula I in which R 2 is hydrogen are also preferred.
• R 1 is preferably hydrogen or (C 1 -C 7 ) alkyl, in particular hydrogen or methyl. The preferred meaning of R is hydrogen or (C 1 -C 7 ) alkyl, especially hydrogen or methyl.
• R 5 is preferably halogen with an atomic number not exceeding 35.
• oxidation of a compound of formula II with a peracid according to aspect a) of the process according to the invention is carried out in a manner known per se.
• Suitable peracids for this oxidation step are peracids such as m-chloroperbenzoic acid, pertrifluoroacetic acid and the like.
• peracids such as m-chloroperbenzoic acid, pertrifluoroacetic acid and the like.
• the reaction is conveniently carried out in a lower carboxylic acid, such as acetic acid, trifluoroacetic acid, propionic acid and the like, or in a mixture of such a carboxylic acid with a suitable inert solvent, such as a chlorinated hydrocarbon, e.g. B. methylene chloride, an aromatic hydrocarbon, e.g. As benzene, toluene and the like, in the presence of a strong mineral acid such as sulfuric acid and the like.
• a suitable inert solvent such as a chlorinated hydrocarbon, e.g. B.
• the oxidation of a compound of formula II is preferably carried out at a temperature between about 0 ° C and about room temperature. It should be noted that a mixture of the 1-oxo and 3-oxo compounds is obtained if both R 11 and R 3 in the starting material of the formula II are hydrogen. If the oxidation is carried out under strongly acidic conditions, the 3-oxo compound predominates, whereas the 1-oxo compound is the predominant product if the reaction is in the absence of a strong mineral acid is carried out. The mixture obtained can be separated using customary methods, such as fractional crystallization and chromatography.
• the oxidation according to aspect b) of the method according to the invention is also carried out according to methods known per se.
• this oxidation lead (IV) carboxylates such as lead tetraacetate or lead (IV) trifluoroacetate
• an inert solvent such as chlorinated hydrocarbons, e.g. As methylene chloride or chloroform, and the like, in the presence of a strong acid such as trifluoroacetic acid and the like.
• the reaction is conveniently carried out in a temperature range from about 0 ° C to about room temperature.
• the reaction according to aspect c) of the process according to the invention is also carried out according to methods known per se. So you can let the starting material react with lead tetraacetate in acetic acid, preferably at about room temperature. If a compound of the formula II in which R 11 and R 31 are hydrogen is used as the starting material, a mixture of the 1-acetoxy-3-oxo and the 3-acetoxy-1-oxo compounds and a 1,3 is obtained -Bis-acetoxy compound of formula 111. The mixture obtained can be separated by customary chromatographic measures.
• reaction of a compound of formula I, wherein R, or R 3 is hydroxy, with a carboxylic anhydride according to aspect d) of the process according to the invention also takes place in a manner known per se, preferably in the presence of a base such as pyridine, dimethylaminopyridine, N-methylpiperidine and the like.
• a base such as pyridine, dimethylaminopyridine, N-methylpiperidine and the like.
• Inert solvents that can be used in this reaction are chlorinated hydrocarbons such as methylene chloride, ethers such as tetrahydrofuran and the like.
• the reaction is conveniently carried out at a temperature in the range from about 0 ° C. to about room temperature.
• the etherification according to aspect e) of the process according to the invention is carried out in a manner known per se, expediently by reacting a compound of the formula I in which R or R 3 is ⁇ OCOR ', preferably acetoxy, or a compound of the formula III with an excess of one lower alkanol containing a catalytic amount of a strong acid such as methanesulfonic acid and the like.
• This reaction is preferably carried out at a temperature between about 0 ° C and about room temperature.
• the deoxidation according to aspect f) of the process according to the invention is also carried out according to methods known per se, expediently by treating a compound of the formula IA with a deoxidizing agent, such as phosphorus trichloride or triphenylphosphine, in an inert solvent, such as chlorinated hydrocarbons, e.g. B. methylene chloride, aromatic hydrocarbons, e.g. B. toluene, ether, e.g. As tetrahydrofuran, and the like, at a temperature between about room temperature and the reflux temperature of the solvent.
• a deoxidizing agent such as phosphorus trichloride or triphenylphosphine
• an inert solvent such as chlorinated hydrocarbons, e.g. B. methylene chloride, aromatic hydrocarbons, e.g. B. toluene, ether, e.g. As tetrahydrofuran, and the like, at a temperature
• R 13 is hydrogen or (C 1 -C 7 ) alkyl and R 5 and R 6 have the above meaning.
• the compound of formula III can be reacted with an a-tosyl alkyl isocyanide in the presence of a base, such as sodium hydride, using a mixture of dimethyl sulfoxide and an ether, such as diethyl ether, dioxane or tetrahydrofuran, as a solvent.
• a base such as sodium hydride
• the reaction temperature can be between about 0 ° C and about 40 ° C, with room temperature being preferred.
• the a-tosyl alkyl isocyanides mentioned above can be prepared according to van Leusen et al., Tetrahedron Letters, 3,487 (1975).
• the compound of formula IV can be reacted with hydrogen at pressures from about atmospheric to 5 atmospheres in the presence of a transition metal catalyst such as Raney nickel using glacial acetic acid as a solvent.
• the reaction temperature is advantageously around room temperature.
• the open-chain amine formed first is not isolated, but spontaneously cyclizes to product IIa.
• the compound of formula IV can be reacted in an ethereal solvent such as tetrahydrofuran with a metal hydride reducing agent such as lithium aluminum hydride.
• the reaction temperature can range from about -20 ° C to about room temperature, with about 0 ° C being preferred.
• the compound of formula V can be reacted with manganese dioxide in an ethereal solvent, such as tetrahydrofuran, or in another suitable solvent, such as toluene.
• the resulting amine spontaneously cyclizes to product IIa.
• the reaction temperature can be between about room temperature and the boiling point of the solvent, with about 40 ° C. being preferred.
• R 14 and R 32 are (C 1 -C 7 ) alkyl and R 5 and R 6 have the above meaning.
• the compound of formula Ila ' can be reacted between about ⁇ 80 ° C and about 0 ° C, preferably at about ⁇ 20 ° C, with an equivalent of a strong base such as lithium diisopropylamide.
• the the resulting anion is treated with the desired alkylating agent, such as a lower alkyl halide or sulfonate.
• the desired alkylating agent such as a lower alkyl halide or sulfonate.
• a mixture of the isomers of the formulas Ila "and Ilb is obtained, which can be separated by customary column chromatography measures.
• R "(C 1 -C 7 ) alkyl, R 7 (C 1 -C 7 ) alkyl, R 8 and R 9 are hydrogen or (C 1 -C 7 ) alkyl and n is an integer from 1 to 6 mean and R 11 , R 31 , R 5 and R 6 have the above meaning.
• a compound of the formula I can in the presence of a base, such as an alkali metal alkoxide, in a polar solvent, such as dimethyl sulfoxide or dimethylformamide, with a haloester, such as Bro ethyl acetate or 3-bromo-propionate are implemented.
• the reaction temperature can range from about -20 ° C to about room temperature, with about 0 ° C being preferred.
• the product of the formula IIh thus obtained can be treated in an aqueous ethereal solvent, such as tetrahydrofuran, with an alkali metal carbonate or hydroxide. Subsequent addition of a strong mineral acid thus gives the corresponding carboxylic acid of the formula IIj.
• a compound of formula IIh may be treated in a C 1 -C 4 -alcohol as a solvent with ammonia or a mono- or di- (C 1 -C 7) alkyl amine and a catalytic amount of its hydrochloride salt.
• the reaction is usually carried out at about 100 ° C using pressure equipment to retain the volatile reactants.
• a compound of the formula IIh can be reacted in an ethereal solvent such as tetrahydrofuran or dioxane with a metal hydride such as lithium aluminum hydride.
• the reaction temperature can be between about -80 ° C and about room temperature, with about 0 ° C being preferred.
• a compound of formula IIc can be in the presence of a base such as an alkali metal alkoxide in a polar solvent such as dimethyl sulfoxide or dimethylformamide with a compound of the formula wherein X is a halide or sulfonate and R 8 , R 9 and n have the above meaning, are reacted.
• the reaction temperature can be between about -20 ° C and about room temperature, with about room temperature being preferred.
• a compound of formula IIc can in a polar aprotic solvent such as dimethylformamide or dimethyl sulfoxide with a base such as an alkali metal alkoxide, e.g. As potassium or sodium methoxide, and then reacted with an alkylating agent such as a (C 1 -C 7 ) alkyl halide or sulfonate.
• a polar aprotic solvent such as dimethylformamide or dimethyl sulfoxide
• a base such as an alkali metal alkoxide, e.g. As potassium or sodium methoxide
• an alkylating agent such as a (C 1 -C 7 ) alkyl halide or sulfonate.
• the reaction temperature can be between about 0 ° C and about room temperature, with about 0 ° C being preferred.
• a compound of the formula IIf or IIh is reacted in an ethereal solvent, such as tetrahydrofuran, with a metal hydride reducing agent, such as lithium aluminum hydride.
• a metal hydride reducing agent such as lithium aluminum hydride.
• the reaction temperature can be between about -20 ° C and about room temperature, with about 0 ° C being preferred.
• a compound of formula IIc can be in the presence of a base, such as an alkali metal alkoxide, in dimethylformamide or dimethyl sulfoxide with a compound of formula wherein Z represents a hydroxyl protective group and X and n have the meaning given above, are reacted.
• a base such as an alkali metal alkoxide
• Z represents a hydroxyl protective group
• X and n have the meaning given above
• a compound of formula IIc can be in the presence of a base, such as an alkali metal alkoxide, in dimethylformamide or dimethyl sulfoxide with a compound of formula where X, R 8 , Rg and n have the above meaning, are implemented.
• a base such as an alkali metal alkoxide, in dimethylformamide or dimethyl sulfoxide with a compound of formula where X, R 8 , Rg and n have the above meaning, are implemented.
• the compounds according to the invention can be used as pharmaceuticals and have sedative and anxiolytic properties.
• These compounds can be used in the form of conventional pharmaceutical preparations; for example, the compounds mentioned can be combined with customary organic or inorganic, inert, pharmaceutical carriers suitable for parenteral or enteral administration, such as, for. As water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oils, gum arabic, polyethylene glycols, petroleum jelly @ or the like can be mixed.
• They can be administered in conventional pharmaceutical forms, for example in solid forms, e.g. As tablets, dragees, capsules, suppositories or the like, or in liquid forms, e.g. B. solutions, suspensions or emulsions.
• the pharmaceutical preparations containing compounds according to the invention can be subjected to conventional pharmaceutical measures, such as sterilization, and they can contain conventional pharmaceutical auxiliaries, such as preservatives, stabilizers, wetting agents, emulsifiers, salts for adjusting the osmotic pressure or buffers.
• conventional pharmaceutical auxiliaries such as preservatives, stabilizers, wetting agents, emulsifiers, salts for adjusting the osmotic pressure or buffers.
• the preparations can also contain other therapeutically active substances.
• a suitable pharmaceutical dosage unit can contain from about 0.1 to about 500 mg of the compounds according to the invention, a dosage range from about 0.1 mg to about 100 mg for oral administration and a dosage range from about 0.1 mg to about 50 mg for parenteral Administration is preferred. In each individual case, however, the specific dosage should be determined according to the individual needs and the professional judgment of the person who administers the compounds mentioned or monitors their administration. It should be noted that the above dosage information is intended to be exemplary only and is not intended to limit the scope and applicability of the present invention in any way.
• drug unit used in this specification refers to individual pharmaceutical units which are suitable as single doses for mammals and each of which contains a predetermined amount of active ingredient together with the required pharmaceutical diluent, carrier or vehicle to achieve the therapeutic effect.
• This test is used when screening for anxiolytic properties.
• mice male mice, 45-54 days old, which had been kept in place for 1 week and were not given any food for about 24 hours, were used.
• the test substances are administered orally to the animals, dispersed in 5% acacia oil, three animals being used per dose.
• metrazole is administered intravenously at a dose of 70 mg / kg (consulsive dose 100 mg / kg) and the animals are observed for protection against convulsions for 30 seconds.
• the number of animals protected from convulsions is determined.
• the dose are protected at which 50% of the animals from the convulsive seizures is expressed as ED so on.
• the approximate ED 50 is calculated using the Miller and Tainter method (Proc. Soc. Exp. Biol. Med. 57: 261, 1944).
• a sample of the product is purified by preparative chromatography (silica gel, 2 mm; 1: 1 mixture of methylene chloride and pentane), and a white solid with a melting point of 87-89 ° C. is obtained.
• a second portion of crystals consisting of 6-chloro-8- (2-chlorophenyl) -1,8-dihydro-8-hydroxy-2-methylindeno [2,1-b] pyrrole-3-carbonitrile, is obtained from ether. Melting point 221-225 ° C. Recrystallization from ether gives pale yellow prisms with a melting point of 232-237 ° C.
• the methanesulfonate of 8-chloro-6- (2-chlorophenyl) -2-methyl-2H, 4H-pyrrolo [3,4-d] [2] benzazepine is prepared by adding equimolar amounts of the free base and methanesulfonic acid to methanol and isolated by precipitation by adding ether. Recrystallization from a mixture of methanol and ether gives the methanesulfonate as orange-colored prisms with a melting point of 200-203 ° C.
• aqueous solution is extracted with 3 x 500 ml ether.
• the ether solutions are combined, washed with 6 x 800 ml of water, dried over anhydrous sodium sulfate and concentrated to 35 g of a dark residue under reduced pressure.
• Purification by column chromatography (silica gel, 500 g; eluent 50% ether in petroleum ether) gives 4- [4-chloro-2- (2-chlorophenyl) phenyl] -5-ethyl-1 H-pyrrole-3-carbonitrile as the first product as whitish prisms with a melting point of 163-164 ° C (after crystallization from a mixture of ether and methylene chloride).
• the methanesulfonate of 8-chloro-6- (2-chlorophenyl) -1,4-dihydro-3-methoxypyrrolo [3,4-d] [2] benzazepin-1 (2H) -one is obtained by dissolving the free base prepared in an excess of methanolic methanesulfonic acid and isolated by precipitation by adding ether. Recrystallization from a mixture of methanol and ether gives this salt as colorless crystals with a melting point of 157-160 ° C.
• the active ingredient is mixed thoroughly with the same amount of lactose, mixed with ingredients 3 and 4 and the rest of the lactose, then the magnesium stearate is added and the mixture is mixed for 3 minutes.
• the mass is pressed into tablets of a suitable size on a suitable press.
• Ingredients 1-4 are mixed in a suitable mixer, granulated with enough distilled water to obtain a suitable consistency, ground and dried in a suitable oven. The mixture is then ground, mixed with the magnesium stearate for 3 minutes and pressed on a suitable press.
• Components 1, 2, 3 and 5 are mixed in a suitable mixer, ground, mixed with the talc and mixed well. It is filled into capsules on a suitable machine.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (3)

Family

ID=27008604

Family Applications (1)

Country Status (9)

Family Cites Families (2)

• 1983
  • 1983-05-16 DE DE8383104815T patent/DE3372369D1/de not_active Expired
  • 1983-05-16 EP EP83104815A patent/EP0094668B1/de not_active Expired
  • 1983-05-16 CA CA000428213A patent/CA1202970A/en not_active Expired
  • 1983-05-16 IL IL68711A patent/IL68711A/xx unknown
  • 1983-05-16 NZ NZ204242A patent/NZ204242A/en unknown
  • 1983-05-17 AU AU14605/83A patent/AU558354B2/en not_active Ceased
  • 1983-05-17 IE IE1148/83A patent/IE55134B1/en unknown
  • 1983-05-17 PH PH28914A patent/PH19004A/en unknown
  • 1983-05-17 DK DK218583A patent/DK218583A/da not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events